Forde PM - Search Results

1

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.

2

Crizotinib in the treatment of non-small-cell lung cancer.

Forde PM, Rudin CM. Forde PM, et al. Expert Opin Pharmacother. 2012 Jun;13(8):1195-201. doi: 10.1517/14656566.2012.688029. Expert Opin Pharmacother. 2012. PMID: 22594847 Review.

3

Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer.

Forde PM, Kelly RJ. Forde PM, et al. J Thorac Oncol. 2013 Jun;8(6):673-84. doi: 10.1097/JTO.0b013e31828b5172. J Thorac Oncol. 2013. PMID: 23591158 Free article.

4

What lies within: novel strategies in immunotherapy for non-small cell lung cancer.

Forde PM, Reiss KA, Zeidan AM, Brahmer JR. Forde PM, et al. Oncologist. 2013;18(11):1203-13. doi: 10.1634/theoncologist.2013-0171. Epub 2013 Oct 8. Oncologist. 2013. PMID: 24105749 Free PMC article. Review.

5

New strategies in lung cancer: translating immunotherapy into clinical practice.

Forde PM, Kelly RJ, Brahmer JR. Forde PM, et al. Clin Cancer Res. 2014 Mar 1;20(5):1067-73. doi: 10.1158/1078-0432.CCR-13-0731. Epub 2014 Jan 27. Clin Cancer Res. 2014. PMID: 24470514 Review.

6

Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.

Forde PM, Hooker CM, Boikos SA, Petrini I, Giaccone G, Rudin CM, Yang SC, Illei PB, Hann CL, Ettinger DS, Brahmer JR, Kelly RJ. Forde PM, et al. J Thorac Oncol. 2014 Mar;9(3):414-8. doi: 10.1097/JTO.0000000000000065. J Thorac Oncol. 2014. PMID: 24518093 Free PMC article.

7

New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer.

Forde PM, Brahmer JR, Kelly RJ. Forde PM, et al. Clin Cancer Res. 2014 May 1;20(9):2244-8. doi: 10.1158/1078-0432.CCR-13-2088. Epub 2014 Mar 18. Clin Cancer Res. 2014. PMID: 24644000 Free PMC article. Review.

8

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Reiss KA, Forde PM, Brahmer JR. Reiss KA, et al. Among authors: forde pm. Immunotherapy. 2014;6(4):459-75. doi: 10.2217/imt.14.9. Immunotherapy. 2014. PMID: 24815784 Free PMC article. Review.

9

Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Lipson EJ, et al. Among authors: forde pm. Semin Oncol. 2015 Aug;42(4):587-600. doi: 10.1053/j.seminoncol.2015.05.013. Epub 2015 Jun 10. Semin Oncol. 2015. PMID: 26320063 Free PMC article. Review.

10

Managing acquired resistance in EGFR-mutated non-small cell lung cancer.

Forde PM, Ettinger DS. Forde PM, et al. Clin Adv Hematol Oncol. 2015 Aug;13(8):528-32. Clin Adv Hematol Oncol. 2015. PMID: 26351816 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

146 results

Search Page